Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.50 and traded as low as $1.35. Pulmatrix shares last traded at $1.42, with a volume of 37,223 shares traded.
Wall Street Analyst Weigh In
Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has an average rating of “Sell”.
Get Our Latest Stock Analysis on PULM
Pulmatrix Price Performance
The firm has a market cap of $5.73 million, a PE ratio of -1.43 and a beta of 1.93. The business has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $1.48.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($2.00) by $1.71.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Pulmatrix stock. BlackRock Inc. purchased a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,899 shares of the biotechnology company’s stock, valued at approximately $93,000. BlackRock Inc. owned about 1.50% of Pulmatrix at the end of the most recent reporting period. 11.84% of the stock is currently owned by institutional investors.
About Pulmatrix
Pulmatrix, Inc (NASDAQ:PULM) is a clinical-stage biopharmaceutical company developing inhaled therapies for respiratory and other diseases. The company’s programs are based on its proprietary iSPERSE dry-powder delivery technology, which is designed to improve the delivery of drug particles to the lungs through a portable inhalation device.
Pulmatrix’s development pipeline has included PUR310, an inhaled formulation of dihydroergotamine intended for the acute treatment of migraine, as well as inhaled therapies aimed at respiratory conditions such as asthma and chronic pulmonary diseases.
Further Reading
- Five stocks we like better than Pulmatrix
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
